Officials of Kuraray, Cyfuse Biomedical, Chiyoda and Zacros meet the press on October 1, 2025 to announce their partnership to develop a mass cultivation technology for stem cells for regenerative medicine using 3D printers. Photo: Jiji Press
Kuraray Co., Cyfuse Biomedical K.K., Chiyoda Corp. and Zacros Corp. will share equipment, necessary substances, analysis methods and safety verification techniques, aiming to establish the mass cultivation technology by 2030, when the regenerative medicine market is seen expanding, according to their announcement on Wednesday.
"We want to bring together our technologies so that we can beef up our strengths (for the launch of commercial production)," Shizuka Akieda, CEO of Cyfuse, a regenerative medicine startup, said at a press conference in Tokyo to announce the four-way project.
Mass cultivation of stem cells is essential for the commercial production of blood vessels, nerves, cartilage and other tissues using 3D printers.
Massive costs have been a challenge, however.
In the joint project, Zacros, a wrapping material maker, will provide cultivation equipment, and Kuraray, a textile and chemical maker, will offer substances to increase cultivation efficiency.
Chiyoda, an engineering company, will analyze the cultivation conditions using artificial intelligence, and bio 3D printers of Cyfuse will be used to create human tissues.
The four companies will consider mass cultivation also for induced pluripotent stem, or iPS, cells and embryonic stem, or ES, cells in the future.
Max: 1500 characters
There are no comments yet. Be the first to comment.